N-(2-hydroxyethyl)-4'-(α-D-mannopyranosyloxy)biphenyl-3-carboxamide | 1295649-81-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(2-hydroxyethyl)-4'-(α-D-mannopyranosyloxy)biphenyl-3-carboxamide
• 英文别名: N-(2-hydroxyethyl)-3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]benzamide；N-(2-hydroxyethyl)-3-[4-[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]benzamide；N-(2-hydroxyethyl)-3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]benzamide
• CAS: 1295649-81-8
• 化学式: C₂₁H₂₅NO₈
• 分子量: 419.431
• InChiKey: NLURUFPXQYULDW-AGRFSFNASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  149
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-[4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydropyran-2-yl]oxyphenyl]benzoic acid 、 C.I.酸性橙108 在 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以76%的产率得到N-(2-hydroxyethyl)-4'-(α-D-mannopyranosyloxy)biphenyl-3-carboxamide
  参考文献：
  名称：

  [EN] MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS MANNOSIDES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明涵盖了用于治疗尿路感染的化合物和方法。

  公开号：

  WO2012109263A1

文献信息

• COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
  申请人：Janetka James W.

  公开号：US20120309701A1

  公开（公告）日：2012-12-06

  The present invention encompasses compounds and methods for treating urinary tract infections.

  本发明涵盖了治疗尿路感染的化合物和方法。
• Compounds and methods for treating bacterial infections
  申请人：Washington University

  公开号：US10273260B2

  公开（公告）日：2019-04-30

  The present invention encompasses compounds and methods for treating urinary tract infections.

  本发明包括治疗尿路感染的化合物和方法。
• Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides
  作者：Zhenfu Han、Jerome S. Pinkner、Bradley Ford、Erik Chorell、Jan M. Crowley、Corinne K. Cusumano、Scott Campbell、Jeffrey P. Henderson、Scott J. Hultgren、James W. Janetka

  DOI：10.1021/jm300165m

  日期：2012.4.26

  Herein, we describe the X-ray structure-based design and optimization of biaryl mannoside FimH inhibitors. Diverse modifications to the biaryl ring to improve druglike physical and pharmacokinetic properties of mannosides were assessed for FimH binding affinity based on their effects on hemagglutination and biofilm formation along with direct FimH binding assays. Substitution on the mannoside phenyl ring ortho to the glycosidic bond results in large potency enhancements several-fold higher than those of corresponding unsubstituted matched pairs and can be rationalized from increased hydrophobic interactions with the FimH hydrophobic ridge (Ile13) or "tyrosine gate" (Tyr137 and Tyr48) also lined by Ile52. The lead mannosides have increased metabolic stability and oral bioavailability as determined from in vitro PAMPA predictive model of cellular permeability and in vivo pharmacokinetic studies in mice, thereby representing advanced preclinical candidates with promising potential as novel therapeutics for the clinical treatment and prevention of recurring urinary tract infections.
• MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Washington University

  公开号：EP2672820B1

  公开（公告）日：2019-04-17
• US8937167B2
  申请人：——

  公开号：US8937167B2

  公开（公告）日：2015-01-20